Time-ordered-expression mRNA may improve melanoma RNA vaccine potency by translating antigen before delayed IL-12 adjuvant expression.
Evidence
This preclinical platform experiment used ADAR-mediated A-to-I editing to delay adjuvant translation by about 12 hours and reported enhanced antitumor immune responses with tumor neoantigen and IL-12 TOE mRNA vaccines.
Caveat
The abstract does not describe human clinical testing, so efficacy and safety remain limited to the reported experimental models.
Simplified
Modified mRNA technology has transformed vaccine development by enabling rapid and precise antigen production. The incorporation of adjuvants may further enhance innate immune activation, thereby improving the efficacy of mRNA vaccines. However, inappropriate vaccine kinetics leading to excessive activation of the innate immune system can inhibit the and impair antigen mRNA translation, ultimately limiting vaccine potency. Herein, we present the development of a time-ordered-expression mRNA (TOE mRNA) based on ADAR-mediated A-to-I base editing. Upon cellular entry, the TOE mRNA initiates immediate antigen translation, while the adjuvant encoded within the same mRNA is translated approximately 12 hours post-antigen expression. This delayed adjuvant expression ensures sustained activation of the mTORC1 pathway and robust antigen expression, effectively overcoming the limitations imposed by suboptimal vaccine kinetics. We demonstrate that vaccines utilizing TOE mRNA encoding a tumor neoantigen (for normal translation) and an IL-12 adjuvant (with delayed translation) elicit significantly enhanced antitumor immune responses. TOE mRNA technology represents a promising platform for advancing next-generation mRNA vaccines with improved efficacy.
Key numbers
76.7%
Target Cell Killing Rate Increase
OVA-specific cell killing rate achieved with TOE mRNA vaccination.
22.3%
Tumor Volume Reduction
Tumor volume compared to the Neo/IL-12 group 10 days post-inoculation.
71.4%
Survival Rate
Persistent survival rate of mice after TOE mRNA vaccination.
Full Text
We can’t show the full text here under this license.
